Calculate drug elimination half-life from Ke, two C-t points, or CL and Vd
Calculate area under the curve using linear trapezoidal, log-linear, or mixed methods
Calculate systemic clearance and volume of distribution from PK data
Calculate absolute and relative bioavailability from AUC comparisons
Predict time to steady state and accumulation from dosing regimen
Calculate the loading dose to achieve target plasma concentration immediately
Assess dose-exposure linearity using power model and confidence intervals
Simulate concentration-time profiles for repeated oral or IV dosing
Calculate mean residence time, mean absorption time, and absorption rate constant
Calculate drug accumulation factor from half-life and dosing interval
Calculate pediatric dose scaling using BSA, weight-based, and age-adjusted methods for Pediatric Study Plan (iPSP) dose justification and clinical trial design
Predict dose modifications for renal impairment studies per FDA/EMA guidance. Dettli method with CKD staging for special population sections
Child-Pugh classification and dose adjustment rationale for hepatic impairment clinical pharmacology studies and NDA submissions
Compare IBW, ABW, LBW, and BSA-based dosing strategies for weight-based dose selection in clinical development programs
Age-adjusted pharmacokinetic considerations and CrCl estimation for geriatric sub-population analysis in clinical pharmacology reviews
Predict drug-drug interaction magnitude from inhibition/induction parameters. FDA classification for DDI risk assessment and labeling recommendations
Calculate loading dose with current level accounting for first-in-human dose selection rationale and clinical trial protocol design
Predict drug removal during hemodialysis and supplemental dosing for renal impairment study design and product labeling
In vitro to in vivo extrapolation of hepatic clearance using well-stirred model
Predict in vivo clearance from microsomal stability half-life data
FDA static model R1/R2/R3 for CYP inhibition and induction risk classification
Calculate fraction unbound in microsomes for IVIVE correction
Calculate Km, Vmax, and CLint from Michaelis-Menten kinetics data
Evaluate P-glycoprotein efflux ratio from Caco-2 or MDCK transport data
Predict renal clearance from GFR, tubular secretion, and reabsorption
Determine Biopharmaceutics Classification System class from solubility and permeability
Target-mediated drug disposition model for monoclonal antibodies
Scale monoclonal antibody PK parameters across species using allometry
Estimate monoclonal antibody half-life from FcRn binding and IgG subclass
Estimate subcutaneous bioavailability relative to IV for biologics
Simulate IV bolus and infusion concentration-time profiles
Simulate oral absorption with first-order Ka and elimination
Two-compartment PK model with distribution and elimination phases
Simulate Emax, sigmoid Emax, and effect-compartment PD models
Simulate probability of target attainment for PK/PD endpoints
Compare IV and oral dosing profiles side by side for bioequivalence
Calculate required subjects for bioequivalence studies with power analysis
Determine optimal sample size for pharmacokinetic studies
Calculate required washout period based on drug half-life for crossover studies
Compare crossover and parallel study designs for clinical PK trials
Convert between common pharmacokinetic units for concentration, dose, and time
Convert between molar (nmol/L) and mass (ng/mL) concentrations
Calculate creatinine clearance (Cockcroft-Gault) and eGFR (CKD-EPI, MDRD)
Calculate corrected QT interval using Bazett, Fridericia, and Framingham formulas
Calculate IV infusion rates, drip rates, and target steady-state concentrations
Convert between CV%, SD, variance on original and log scales for BE study design and popPK analysis
Predict in vivo clearance from hepatocyte stability data using HPGL scaling and well-stirred model
Calculate CYP enzyme contributions (fm) from selective inhibitor data for DDI vulnerability assessment
Reference table of MPPGL, HPGL, liver weight, and hepatic blood flow across species for IVIVE
Calculate percentage of dosing interval with free drug above MIC for time-dependent antimicrobials
Calculate AUC/MIC and fAUC/MIC ratios for vancomycin TDM, fluoroquinolone dosing, and AUC-guided therapy
Calculate Cmax/MIC and fCmax/MIC ratios for aminoglycoside dose optimization and once-daily dosing
Population-level Monte Carlo simulation of probability of target attainment across dose and MIC ranges
Look up EUCAST MIC breakpoints with PK/PD indices and targets for common organism-antibiotic combinations
Predict molecular ADMET properties using consensus ML models (ChemBERTa + ADMETlab) from SMILES or drug name
Find structurally similar approved drugs with known PK properties using MolFormer molecular fingerprints
Multi-model toxicity risk assessment combining ADMETlab, DeepChem, and structural alerts (PAINS/Brenk)
ML-based ADMET property prediction from SMILES or drug name via ADMETlab 3.0
Evaluate Lipinski, Veber, Egan, Ghose drug-likeness rules with QED and SA scores
Predict CYP1A2, 2C9, 2C19, 2D6, 3A4 inhibition and substrate status from molecular structure
Predict blood-brain barrier penetration probability and CNS MPO score
Predict hERG channel inhibition probability and QT prolongation risk from structure
Check drug-drug interactions from FDA-approved label text via DailyMed and openFDA
Search and compare regulatory guidances across FDA, EMA, ICH, and Health Canada with AI summaries and cross-agency comparison
Search ClinicalTrials.gov with intelligent PK study type classification, endpoint extraction, and competitive landscape analysis
Search and compare drug approvals across FDA, EMA, and Health Canada with interactive timelines and cross-agency comparison
Analyze Orange Book patents and exclusivities with generic entry date calculation, patent thicket scoring, and Paragraph IV opportunity identification
Search, navigate, and compare FDA drug labels with section-level SPL parsing, AI-powered diff, and cross-links to PK calculators
Analyze FDA FAERS adverse events with PRR/ROR disproportionality metrics, signal detection, trend charts, and AI interpretation
Look up CPIC/DPWG pharmacogenomic dosing recommendations by drug and gene with evidence levels
Explore drug-target relationships, mechanisms of action, and disease associations via Open Targets Platform
Look up CYP enzyme substrates, inhibitors, and inducers from FDA DDI guidance tables for drug metabolism assessment
Search EMA Open Data for EU-authorized medicines with authorization dates, therapeutic areas, ATC codes, and EPAR links
Search NADAC drug pricing, compare brand vs generic, view price trends, check shortage status. Free CMS data in a modern interface.
Monitor current and resolved FDA drug shortages. Get alerts when shortages are resolved. Check pricing for alternatives.
Look up population distributions for PK covariates (SCr, eGFR, albumin, weight, BMI, ALT, AST) from NHANES by age and sex
Explore FDA Purple Book data. Find biosimilars, check interchangeability status, view reference product relationships, compare pricing.
View eGFR population distributions by age and sex from NHANES with CKD stage prevalence and patient percentile
Population distributions for weight, BMI, lean mass, and fat mass by age and sex from NHANES for obesity dosing context
Calculate CYP enzyme maturation fraction (Fmat) by age using the Hill equation for CYP3A4, CYP2D6, CYP1A2, CYP2C9, CYP2C19
Calculate UGT enzyme maturation (UGT2B7, UGT1A1, UGT1A6, UGT1A9) by age using the Hill equation
Scale adult doses and clearances to pediatric values using allometric, Anderson & Holford, BSA-based, and linear per-kg methods
Calculate pediatric eGFR using Schwartz, FAS, and CKiD U25 equations with CKD staging
Comprehensive neonatal physiological maturation assessment: GFR, CYP activity, protein binding, body water, gastric pH
Determine pediatric study requirements under FDA PREA/BPCA and EMA PIP with age groups, study types, and waivers
Compute 2x2 crossover ANOVA decomposition for BE studies with F-tests, p-values, intra-subject CV%, and MSE
Calculate 90% CI for bioequivalence from summary statistics (GMR, CV%, N) using TOST procedure
Calculate geometric mean ratio and 90% confidence interval for bioequivalence against 80-125% limits
Calculate reference-scaled average bioequivalence for highly variable drugs with Swr threshold and scaled limits
Calculate bioequivalence for narrow therapeutic index drugs with tightened 90-111% limits
Explore how sample size and intra-subject CV% affect statistical power for bioequivalence studies
Determine optimal regulatory pathway: ANDA, 505(b)(2), or product-specific with biowaiver eligibility
Compare pharmacokinetic models using AIC, BIC, and likelihood ratio test from OFV
Calculate eta-shrinkage and epsilon-shrinkage from NONMEM PopPK model output
Convert omega² to CV%, SD, and geometric CV for PopPK models with typical parameter ranges
Visualize covariate effects on PK parameters as a forest plot with clinical significance bounds
Analyze CWRES and IWRES residuals from NONMEM PopPK models for bias and outlier detection
Learn to interpret Visual Predictive Checks with annotated examples covering good fit, overprediction, and pcVPC
Calculate D-optimal sampling times for PK studies to maximize Fisher Information Matrix
Calculate Therapeutic Index (TD50/ED50) and Certain Safety Factor (TD1/ED99) for drug safety margins
Calculate AUC and Cmax exposure margins from animal NOAEL to human therapeutic dose per ICH M3/S9
Calculate maximum recommended starting dose (MRSD) for first-in-human trials using FDA BSA or allometric methods
Perform concentration-QTc analysis with linear regression, 90% CI, and ICH E14 threshold assessment
Fit logistic regression to binary exposure-response data with EC50, odds ratio, and predicted probabilities
Scale PK parameters across species using allometric exponents to predict human CL and Vd from preclinical data
Detect flip-flop kinetics by comparing oral vs IV half-lives or ka vs ke
Look up published pharmacokinetic parameters (CL, Vd, t1/2, F, fu) for common drugs
Reference database of organ weights, blood flows, tissue volumes from ICRP Publication 89
Fit power model (Y = a × X^b) for dose proportionality assessment or allometric scaling
Visualize antibody-drug conjugate PK: total antibody, conjugated antibody, and free payload profiles with DAR effects
Estimate mAb half-life from FcRn binding affinity (KD at pH 6.0), isoelectric point, and molecular weight
Correct phenytoin levels for low albumin and renal impairment using the Winter-Tozer equation
Optimize antimicrobial dosing regimens based on PK/PD targets for beta-lactams, fluoroquinolones, aminoglycosides
Calculate geometric mean, geometric CV%, confidence intervals, and descriptive statistics from PK data
Predict food effect direction and magnitude based on BCS class, logP, and formulation type with FDA meal specs
Estimate dose adjustments when switching formulation types (IR, ER, DR, ODT) based on BCS and relative bioavailability
Fit Weibull dissolution models and establish IVIVC (Level A/B/C) between in vitro dissolution and in vivo absorption
Generate clinical pharmacology study checklist for FDA NDA, ANDA, BLA, and 505(b)(2) submissions
Compare regulatory requirements across FDA, EMA, Health Canada, and WHO for bioequivalence, DDI, pediatric, QT assessment, and more